Scott Higham

Washington, D.C.

Investigative reporter

Education: Stony Brook University, BA in history; Columbia Graduate School of Journalism, MS; Suffolk Community College, AS, Criminal Justice

Scott Higham is a two-time Pulitzer Prize-winning reporter on the Investigative Unit at The Washington Post. Higham joined The Post in 2000. For the past six years, he has examined the confluence of forces fueling the opioid epidemic. He received Emmy, Peabody, George Polk, and DuPont awards for his work in 2017 and 2018. In 2019, he was a lead reporter on The Post’s “Opioid Files” investigation, which was recognized as a Pulitzer Prize finalist for public service. He is the co-author of American Cartel: Inside the Battle to Bring Down the Opioid Industry. In 2002, he shared the Pulitzer for i
Latest from Scott Higham

Overview: From Mexican labs to U.S. streets, a lethal pipeline

The Washington Post traced the fentanyl crisis from the back alleys of northern Mexico, to official Washington. U.S. border authorities are now overwhelmed.

December 15, 2022

Cause of death: Washington faltered as fentanyl gripped America

Fentanyl presented the biggest challenge of the Drug Enforcement Administration’s 50-year history. It faltered, according to former agents and DEA officials.

December 12, 2022

American Cartel: Inside the battle to bring down the opioid industry

An adaptation from Scott Higham and Sari Horwitz’s book, “American Cartel,” reveals how lobbyists, lawmakers and K Street attorneys thwarted efforts to stop the deadly flow of pain pills.

July 7, 2022

Judge rejects claim distributors fueled W.Va. community’s opioid crisis

Judge David A. Faber dismissed the argument made by Cabell County and its seat, Huntington, that three drug distributors bore responsibility for the consequences of an inundation of opioids.

July 4, 2022

The ‘kingpin’ of opioid makers

A cache of more than 1.4 million newly released records exposes the inner workings of the nation’s largest opioid manufacturer. Today on “Post Reports,” we go inside the sales machine at Mallinckrodt.

May 11, 2022

Inside the sales machine of the ‘kingpin’ of opioid makers

More than a quarter of top prescribers ranked by Mallinckrodt Pharmaceuticals during the height of the pain pill epidemic, in 2013, were later convicted of crimes related to their medical practices, had their medical licenses suspended or revoked, or paid state and federal fines after being accused of wrongdoing, according to a Washington Post analysis.

May 10, 2022

More than 100 billion pain pills saturated the nation over nine years

New DEA data reveals that 24 billion additional pills than previously known to the public were distributed during the opioid epidemic.

January 14, 2020

More than 100 billion pain pills saturated the nation over nine years

New DEA data reveals that 24 billion additional pills than previously known to the public were distributed during the opioid epidemic.

January 14, 2020

Could the DEA have stopped the opioid epidemic by cutting off the supply?

Congress and others want the supply restricted to curb abuse, but former DEA officials say it cannot be done without hurting legitimate pain patients.

December 28, 2019

Could the DEA have stopped the opioid epidemic by cutting off the supply?

Congress and others want the supply restricted to curb abuse, but former DEA officials say it cannot be done without hurting legitimate pain patients.

December 28, 2019